Abiopharma

🔍 Meister Keith A. (Executive)

Company: GeneDx Holdings Corp. (WGS)

Report Date: 2026-06-18

Detailed Transactions and Holdings:

• Acquired 3,576 shares of Class A Common Stock (Direct)
  Date: 2026-06-18 | Code: M | equity_swap_involved: 0 | shares_owned_after: 23,705.00 | transaction_form_type: 4 | Footnotes: F1
• Holds 0 shares of Class A Common Stock (Direct)
  Date: 2026-06-18 | Code: H | nature_of_ownership: See footnote | shares_owned_after: 4,784,570.00 | Footnotes: F2
• Holds 0 shares of Class A Common Stock (Direct)
  Date: 2026-06-18 | Code: H | nature_of_ownership: See footnote | shares_owned_after: 333,144.00 | Footnotes: F3
• Acquired 4,248 shares of Restricted Stock Unit (Derivative)
  Date: 2026-06-18 | Code: A | equity_swap_involved: 0 | shares_owned_after: 4,248.00 | transaction_form_type: 4 | Footnotes: F1, F4, F4
• Sold 3,576 shares of Restricted Stock Unit (Derivative)
  Date: 2026-06-18 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F5, F5

Footnotes:

• F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
• F2: Investment funds advised by Corvex Management LP ("Corvex") are the direct holders of the securities reported in this row. The Reporting Person may be deemed to indirectly beneficially own these shares by virtue of his control of the general partner of Corvex.
• F3: CMLS Holdings LLC ("CMLS Holdings") is the direct holder of the securities reported in this row. The Reporting Person is one of two members of the Board of Managers of CMLS Holdings, and he shares voting and investment discretion with respect to securities held of record by CMLS Holdings.
• F4: The entire award shall vest on the earlier of the (i) date of the 2027 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date.
• F5: The entire award vested or vests on the earlier of the: (i) date of the 2026 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date.
• REMARKS: The Reporting Person disclaims beneficial ownership of the securities reported on this Form 4 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 under the Securities Exchange Act of 1934, as amended, or for any other purpose.